Table 2.

Comparison between ongoing phase 3 cardiovascular outcomes trials.

	HORIZON (Pelacarsen)	OCEAN(a)-Outcomes (Olpasiran)
Sponsor (Phase)	Novartis (P3)	Amgen (P3)
Study Design	Randomized double-blind, placebo-controlled, multicenter trial	Randomized double-blind, placebo-controlled, multicenter trial
Population	Age 18 to 80 years N = 7680	Age 18 to 85 years N∼6000
Mechanism	Antisense oligonucleotides (ASO)	Small interfering RNA (siRNA)
Intervention	SC injection Q4 weeks	SC injection Q12 weeks
Key Inclusion Criteria	Lp(a) ≥ 70 mg/dLCVD, as evidence by either: ○MI (≥ 3 months to ≤ 10 yrs) ○Ischemic stroke (≥ 3 months to ≤ 10 yrs) ○Symptomatic PAD	Lp(a) > 200 nmol/LASCVD, as evidence by either: ○MI ○Coronary Revascularization with PCI + 1 additional risk factor
Primary Endpoint	Cardiovascular death, nonfatal MI, non-fatal stroke and urgent coronary revascularization requiring hospitalization (∼4.25 years)	CHD death, MI, urgent coronary revascularization
Status	Enrollment completed	Enrollment ongoing

P3=phase 3, SC=subcutaneous, CVD=cardiovascular disease, MI=myocardial infarction, PAD=peripheral arterial disease, PCI=percutaneous coronary intervention.